TA930 · STA

177Lu vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies

October 2023

Source documents

Final Appraisal DocumentAppraisal Consultation DocumentCommittee PapersScopeScope Consultation Comments

Intervention

177lu vipivotide tetraxetan (lutetium 177)

Condition

psma-positive hormone-relapsed metastatic prostate canceroncology · metastatic

Special considerations

Equality issues raised